Advances in Frontline Gastric, GEJ, and Esophageal Adenocarcinoma From ESMO 2025

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss current treatment standards in advanced gastric/GEJ cancer.

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss the implications of findings from the phase 2 EDGE-Gastric trial.

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, detail the design of the phase 3 STAR-221 trial comparing domvanalimab plus zimberelimab and FOLFOX with nivolumab plus chemotherapy for first-line advanced gastric, GEJ, or esophageal adenocarcinoma. They discuss why nivolumab plus chemotherapy serves as an appropriate control arm and the importance of head-to-head evidence in clarifying comparative benefit across immunotherapy combinations. They review the study’s primary endpoints and overall goals, including survival outcomes and the potential to redefine the frontline standard.

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss the potential clinical implications of the investigation of domvanalimab plus zimberelimab and FOLFOX in gastric/GEJ/esophageal adenocarcinoma.

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss ongoing trials that could help refine the gastric/GEJ cancer treatment paradigm.

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss other key gastric cancer data presented at the 2025 ESMO Congress.